There may be up to a tenfold difference in risk for infants who are currently treated identically under clinical guidelines. The analysis is an important step toward more personalized care.
Leading scientists joined forces to explore how the microbes that live in and on our bodies can be leveraged to provide real-world solutions and improve health care.
On March 29, 2025, the University of Utah received a revised Notice of Award from the National Center for Advancing Translational Sciences restoring funding to the UM1 grant supporting the...
Since 2019, the University of Utah has been developing the world’s most advanced “neuroprosthesis” — an artificial upper arm and hand that is controlled by the user’s thoughts. Named the...
Health sciences research has more than doubled in size over the past 12 years, a trajectory that highlights U of U Health as a destination for leading faculty, learners, and...
The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.
The therapy increases the amount of blood the heart can pump and dramatically improves survival, in what a paper describing the results calls “an unprecedented recovery of cardiac function.”
